Akari Therapeutics CEO Unveils Vision for Next-Generation ADC Cancer Therapies

Abizer Gaslightwala, President and CEO of Akari Therapeutics, has outlined the company's strategic focus on advancing Antibody Drug Conjugates (ADCs) in the oncology sector, leveraging a novel payload technology acquired through the Peak Bio merger. This technology uniquely activates the patient's immune system to target and kill cancer cells, offering a promising avenue for overcoming resistance mechanisms and reducing toxicities associated with current ADC therapies.

Under Gaslightwala's leadership, Akari Therapeutics is prioritizing the development of its lead ADC molecule, which is in advanced preclinical testing, and is rapidly progressing a second novel ADC. The company's innovative payload targets RNA splicing, a strategy that not only aims to kill cancer cells but also robustly activates the immune system, potentially leading to longer and more durable treatment effects.

Gaslightwala's vision positions Akari as a potential new standard in ADC payloads, with the ambition to become the payload of choice for future ADC therapies. The company is focused on validating its novel payload's efficacy and immune-activating properties, with plans to release more data in 2025. Additionally, Akari is developing a next-generation ADC molecule targeting solid cancer tumors, aiming to achieve 'First-in-Class' and 'Best-in-Class' status in the competitive oncology therapeutics landscape.